LH

Lori Hu

Managing Director at Vertex Ventures HC

San Francisco Bay Area

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $200,000.00
  • Target Investment:

    $150,000.00

Skills

Strategy
Venture Capital
Pharmaceutical Industry
Corporate Development
Business Strategy
Emerging Markets
Mergers & Acquisitions
China Business Development
Business Development
Licensing
Biotechnology
Management Consulting
Lifesciences
Mergers
Growth Strategies
Medical Devices
Acquisitions
Greater China
Life Sciences
Financial Modeling

Education

Work Experience

  • Managing Director

    2015

    Vertex Ventures HC (www.vertexventureshc.com) is part of a global venture fund network under Vertex Venture Holdings, a fund anchored by Temasek Holdings, with offices in San Francisco and Boston. Vertex Ventures HC invests globally in various sectors of the healthcare industry, including biopharmaceuticals, medical devices and digital health with $550M assets under management.

  • Board Observer

    2023

  • Board Director

    2022

  • Board Director

    2018

    Glycan-mediated immune regulation to treat cancer and inflammatory diseases

Indapta Therapeutics

2022

  • Board Director

    2022

    NK cell therapy

  • Board Director

    2021

    Miniaturized neuromodulation

2019 - 2024

  • Board Director

    2019 - 2024

    Clinical-stage targeted oncology company (NASDAQ: ELEV)

Ivantis, Inc

2015 - 2022

  • Board Observer

    2015 - 2022

BlackThorn Therapeutics

2018 - 2020

  • Board Director

    2018 - 2020

    Precision neuroscience co (now part of Neumora)

2014 - 2015

  • VC Associate

    2014 - 2015

    Evaluate early-stage healthcare and biotech opportunities for SR One, GlaxoSmithKline's independent corporate healthcare venture capital fund